Together, we’ll achieve more.

Improving upon existing SureSeq technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (right) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The IGK Breakapart probe consists of a 183kb probe, labeled in red, covering a part of the distal IGK Variable region and a green probe, covering a 606kb region including the D2S2216 and D2S2510 markers which is telomeric to the Joining segments and the Constant segment of IGK. The IGL product consists of a 278kb probe, labeled in red, centromeric to the IGL Variable region and covering the MAPK1 gene, and a green probe, covering a 307kb region telomeric to the IGL Constant segment, including the BCR gene.

Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (right) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.